NDAORALCAPSULE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VANCOCIN HYDROCHLORIDE (vancomycin hydrochloride) by ANI Pharmaceuticals is clinical pharmacology vancomycin is poorly absorbed after oral administration. First approved in 1986.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANCOCIN HYDROCHLORIDE is vancomycin HCl, an intravenous glycopeptide antibiotic approved in 1986 for serious gram-positive infections including Staphylococcus aureus and enterococci. It works by inhibiting bacterial cell-wall biosynthesis and is poorly absorbed orally, requiring IV administration for systemic infections. The drug achieves mean plasma concentrations of ~63 mcg/mL post-infusion with a 4-6 hour half-life in patients with normal renal function.
LOE Approaching
Lifecycle stage indicates declining revenue trajectory; commercial teams are focused on market defense and cost management rather than growth expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…
Worked on VANCOCIN HYDROCHLORIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.